Ground-breaking Alzheimers blood test
At the European Academy of Neurology Congress in Helsinki, researchers unveiled a ground breaking blood test that could revolutionize Alzheimer’s disease management by identifying
Donanemab and Lecanemab rejected for the NHS
Two innovative Alzheimer’s drugs, Donanemab and Lecanemab, have been rejected by the NHS due to their exorbitant cost and limited impact. These are the first treatments to slow the disease, potentially extending
- « Previous
- 1
- 2